Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size, Status and Forecast 2020-2026

August 2020 | 97 pages | ID: GE72ADF67BE8EN
QYResearch

Abstracts

This report focuses on the global Alpha-1 Antitrypsin Deficiency Augmentation Therapy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Alpha-1 Antitrypsin Deficiency Augmentation Therapy development in North America, Europe and Asia-Pacific.

The key players covered in this study

• Grifols
• CSL
• Baxter
• Kamada
• Takeda
• Abeona

Market segment by Type, the product can be split into

• Glassia
• Aralast NP
• Prolastin C
• Others

Market segment by Application, split into

• Hospitals
• Specialty Clinics

Market segment by Regions/Countries, this report covers

• North America
• Europe
• Asia-Pacific

The study objectives of this report are:

• To analyze global Alpha-1 Antitrypsin Deficiency Augmentation Therapy status, future forecast, growth opportunity, key market and key players.
• To present the Alpha-1 Antitrypsin Deficiency Augmentation Therapy development in North America, Europe and Asia-Pacific.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Alpha-1 Antitrypsin Deficiency Augmentation Therapy are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue
1.4 Market Analysis by Type
  1.4.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Glassia
  1.4.3 Aralast NP
  1.4.4 Prolastin C
  1.4.5 Others
1.5 Market by Application
  1.5.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application: 2020 VS 2026
  1.5.2 Hospitals
  1.5.3 Specialty Clinics
1.6 Coronavirus Disease 2019 (Covid-19): Alpha-1 Antitrypsin Deficiency Augmentation Therapy Industry Impact
  1.6.1 How the Covid-19 is Affecting the Alpha-1 Antitrypsin Deficiency Augmentation Therapy Industry
    1.6.1.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Alpha-1 Antitrypsin Deficiency Augmentation Therapy Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Perspective (2015-2026)
2.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Growth Trends by Regions
  2.2.1 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Historic Market Share by Regions (2015-2020)
  2.2.3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Growth Strategy
  2.3.6 Primary Interviews with Key Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players by Market Size
  3.1.1 Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players by Revenue (2015-2020)
  3.1.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Players (2015-2020)
  3.1.3 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Concentration Ratio
  3.2.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in 2019
3.3 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Key Players Head office and Area Served
3.4 Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Solution and Service
3.5 Date of Enter into Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Historic Market Size by Type (2015-2020)
4.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Type (2021-2026)

5 ALPHA-1 ANTITRYPSIN DEFICIENCY AUGMENTATION THERAPY BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2015-2020)
5.2 Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2015-2020)
6.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Key Players in North America (2019-2020)
6.3 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2015-2020)
6.4 North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2015-2020)
7.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Key Players in Europe (2019-2020)
7.3 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2015-2020)
7.4 Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2015-2020)

8 ASIA-PACIFIC

8.1 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size (2015-2020)
8.2 Alpha-1 Antitrypsin Deficiency Augmentation Therapy Key Players in Asia-Pacific (2019-2020)
8.3 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2015-2020)
8.4 Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2015-2020)
(2015-2020)
(2015-2020)

9 KEY PLAYERS PROFILES

9.1 Grifols
  9.1.1 Grifols Company Details
  9.1.2 Grifols Business Overview and Its Total Revenue
  9.1.3 Grifols Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
  9.1.4 Grifols Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020))
  9.1.5 Grifols Recent Development
9.2 CSL
  9.2.1 CSL Company Details
  9.2.2 CSL Business Overview and Its Total Revenue
  9.2.3 CSL Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
  9.2.4 CSL Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
  9.2.5 CSL Recent Development
9.3 Baxter
  9.3.1 Baxter Company Details
  9.3.2 Baxter Business Overview and Its Total Revenue
  9.3.3 Baxter Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
  9.3.4 Baxter Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
  9.3.5 Baxter Recent Development
9.4 Kamada
  9.4.1 Kamada Company Details
  9.4.2 Kamada Business Overview and Its Total Revenue
  9.4.3 Kamada Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
  9.4.4 Kamada Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
  9.4.5 Kamada Recent Development
9.5 Takeda
  9.5.1 Takeda Company Details
  9.5.2 Takeda Business Overview and Its Total Revenue
  9.5.3 Takeda Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
  9.5.4 Takeda Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
  9.5.5 Takeda Recent Development
9.6 Abeona
  9.6.1 Abeona Company Details
  9.6.2 Abeona Business Overview and Its Total Revenue
  9.6.3 Abeona Alpha-1 Antitrypsin Deficiency Augmentation Therapy Introduction
  9.6.4 Abeona Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
  9.6.5 Abeona Recent Development

10 ANALYST'S VIEWPOINTS/CONCLUSIONS

11 APPENDIX

11.1 Research Methodology
  11.1.1 Methodology/Research Approach
  11.1.2 Data Source
11.2 Disclaimer
11.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Key Market Segments
Table 2. Key Players Covered: Ranking by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue
Table 3. Ranking of Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Glassia
Table 6. Key Players of Aralast NP
Table 7. Key Players of Prolastin C
Table 8. Key Players of Others
Table 9. COVID-19 Impact Global Market: (Four Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Forecast Scenarios)
Table 10. Opportunities and Trends for Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players in the COVID-19 Landscape
Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 12. Key Regions/Countries Measures against Covid-19 Impact
Table 13. Proposal for Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players to Combat Covid-19 Impact
Table 14. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 15. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Regions (US$ Million): 2020 VS 2026
Table 16. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Regions (2015-2020) (US$ Million)
Table 17. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Regions (2015-2020)
Table 18. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 19. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Regions (2021-2026)
Table 20. Market Top Trends
Table 21. Key Drivers: Impact Analysis
Table 22. Key Challenges
Table 23. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Growth Strategy
Table 24. Main Points Interviewed from Key Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players
Table 25. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue by Players (2015-2020) (Million US$)
Table 26. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Players (2015-2020)
Table 27. Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy as of 2019)
Table 28. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy by Players Market Concentration Ratio (CR5 and HHI)
Table 29. Key Players Headquarters and Area Served
Table 30. Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Product Solution and Service
Table 31. Date of Enter into Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2015-2020) (Million US$)
Table 34. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Share by Type (2015-2020)
Table 35. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue Market Share by Type (2021-2026)
Table 36. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Share by Application (2015-2020)
Table 37. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2015-2020) (Million US$)
Table 38. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size Share by Application (2021-2026)
Table 39. North America Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (2019-2020) (Million US$)
Table 40. North America Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share (2019-2020)
Table 41. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2015-2020) (Million US$)
Table 42. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type (2015-2020)
Table 43. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2015-2020) (Million US$)
Table 44. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application (2015-2020)
Table 45. Europe Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (2019-2020) (Million US$)
Table 46. Europe Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share (2019-2020)
Table 47. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2015-2020) (Million US$)
Table 48. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type (2015-2020)
Table 49. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2015-2020) (Million US$)
Table 50. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application (2015-2020)
Table 51. Asia-Pacific Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue (2019-2020) (Million US$)
Table 52. Asia-Pacific Key Players Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share (2019-2020)
Table 53. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Type (2015-2020) (Million US$)
Table 54. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type (2015-2020)
Table 55. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size by Application (2015-2020) (Million US$)
Table 56. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application (2015-2020)
Table 57. Grifols Company Details
Table 58. Grifols Business Overview
Table 59. Grifols Product
Table 60. Grifols Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020) (Million US$)
Table 61. Grifols Recent Development
Table 62. CSL Company Details
Table 63. CSL Business Overview
Table 64. CSL Product
Table 65. CSL Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020) (Million US$)
Table 66. CSL Recent Development
Table 67. Baxter Company Details
Table 68. Baxter Business Overview
Table 69. Baxter Product
Table 70. Baxter Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020) (Million US$)
Table 71. Baxter Recent Development
Table 72. Kamada Company Details
Table 73. Kamada Business Overview
Table 74. Kamada Product
Table 75. Kamada Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020) (Million US$)
Table 76. Kamada Recent Development
Table 77. Takeda Company Details
Table 78. Takeda Business Overview
Table 79. Takeda Product
Table 80. Takeda Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020) (Million US$)
Table 81. Takeda Recent Development
Table 82. Abeona Company Details
Table 83. Abeona Business Overview
Table 84. Abeona Product
Table 85. Abeona Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020) (Million US$)
Table 86. Abeona Recent Development
Table 87. Research Programs/Design for This Report
Table 88. Key Data Information from Secondary Sources
Table 89. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Type: 2020 VS 2026
Figure 2. Glassia Features
Figure 3. Aralast NP Features
Figure 4. Prolastin C Features
Figure 5. Others Features
Figure 6. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Application: 2020 VS 2026
Figure 7. Hospitals Case Studies
Figure 8. Specialty Clinics Case Studies
Figure 9. Alpha-1 Antitrypsin Deficiency Augmentation Therapy Report Years Considered
Figure 10. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Regions: 2020 VS 2026
Figure 12. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Share by Players in 2019
Figure 15. Global Top Alpha-1 Antitrypsin Deficiency Augmentation Therapy Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Alpha-1 Antitrypsin Deficiency Augmentation Therapy as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Alpha-1 Antitrypsin Deficiency Augmentation Therapy Revenue in 2019
Figure 17. North America Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Asia-Pacific Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Grifols Total Revenue (US$ Million): 2019 Compared with 2018
Figure 21. Grifols Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
Figure 22. CSL Total Revenue (US$ Million): 2019 Compared with 2018
Figure 23. CSL Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
Figure 24. Baxter Total Revenue (US$ Million): 2019 Compared with 2018
Figure 25. Baxter Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
Figure 26. Kamada Total Revenue (US$ Million): 2019 Compared with 2018
Figure 27. Kamada Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
Figure 28. Takeda Total Revenue (US$ Million): 2019 Compared with 2018
Figure 29. Takeda Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
Figure 30. Abeona Total Revenue (US$ Million): 2019 Compared with 2018
Figure 31. Abeona Revenue Growth Rate in Alpha-1 Antitrypsin Deficiency Augmentation Therapy Business (2015-2020)
Figure 32. Bottom-up and Top-down Approaches for This Report
Figure 33. Data Triangulation
Figure 34. Key Executives Interviewed